Table 4 Initial characteristics of interval tumors and tumors detected within PEDBC
Characteristics | Interval tumors N (%) (n = 43) | Screening tumors N (%) (n = 299) |
|---|---|---|
Age | ||
50-59 | 30 (69.8) | 187 (62.5) |
60-69 | 13 (30.2) | 112 (37.5) |
Total | 43 (100.0) | 299 (100.0) |
Stage ** | ||
0 | 4 (9.5) | 35 (15.6) |
I | 10 (23.3) | 111 (50.0) |
II | 16 (37.2) | 59 (26.3) |
III | 6 (14.0) | 14 (6.3) |
IV | 6 (14.0) | 2 (0.9) |
Total | 42 (100.0) | 224 (100.0) |
Tumor size (cm) ** | ||
≤ 9 | 3 (8.1) | 60 (27.3) |
10-14 | 6 (16.2) | 55 (25.0) |
15-19 | 6 (16.2) | 42 (19.1) |
20-29 | 12 (32.4) | 44 (20.0) |
30-49 | 8 (21.6) | 14 (6.4) |
≥50 | 2 (5.4) | 5 (2.3) |
Total | 37 (100.0) | 220 (100.0) |
Lymph nodes** | ||
0 | 20 (54.1) | 150 (71.8) |
1-3 | 12 (32.4) | 35 (16.7) |
>3 | 5 (13.5) | 16 (7.7) |
Total | 37 (100.0) | 209 (100.0) |
Histological grade** | ||
Good | 1 (3.4) | 32 (21..8) |
Moderate | 17 (58.6) | 81 (55.1) |
Poor | 11 (37.9) | 34 (23.1) |
Total | 29 (100.0) | 147 (100.0) |
Histology | ||
Invasive | 38 (90.5) | 196 (86.0) |
In situ | 4 (9.5) | 32 (14.0) |
Total | 42 (100.0) | 228 (100.0) |
Estrogen receptor | ||
Positive | 30 (75.0) | 180 (83.3) |
Negative | 10 (25.0) | 36 (16.7) |
Total | 40 (100.0) | 216 (100.0) |
Progesterone receptor** | ||
Positive | 20 (50.0) | 158 (73.1) |
Negative | 20 (50.0) | 58 (26.9) |
Total | 40 (100.0) | 216 (100.0) |
HER2 | ||
Positive | 10 (27.0) | 39 (22.5) |
Negative | 27 (73.0) | 134 (77.5) |
Total | 37 (100.0) | 173 (100.0) |
Molecular subtype | ||
Luminal A | 21 (56.8) | 121 (69.9) |
Luminal B | 9 (24.3) | 28 (16.2) |
HER2-overexpressed | 1 (2.7) | 11 (6.4) |
Triple Negative | 6 (16.2) | 13 (7.5) |
Total | 37 (100.0) | 173 (100.0) |